. (2012). Srp20 regulates TrkB pre-mRNA splicing to generate TrkB-Shc transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 123 (1), 159-171.
Introduction
Multiple lines of evidence exist suggesting that dysfunction in brain-derived neurotrophic factor (BDNF) signaling may contribute to and promote neurodegeneration in Alzheimer's disease (AD) (Phillips et al. 1991; Connor et al. 1997; Allen et al. 1999; Ferrer et al. 1999) . At present, the mechanisms underlying the deficit in BDNF signaling in AD have not been defined. In this study, we focus on the principal component of the BDNF signaling pathway, the tropomyosin receptor kinase B (TrkB) receptor. TrkB is a receptor tyrosine kinase that resides in the cell plasma membrane. Binding to extracellular BDNF leads to dimerization of monomeric TrkB receptors and transphosphorylation of key tyrosine residues in the C-terminal domain that couple it to downstream signaling pathways that promote neuronal survival, growth, differentiation, and plasticity including mitogen-activated protein kinase kinase, phosphatidyl inositol 3 kinase, and phospholipase C-gamma (Biffo et al. 1995; Eide et al. 1996; Ninkina et al. 1996; Snapyan et al. 2009 ).
In the human brain, three major isoforms of TrkB are expressed: the full-length (TrkB-TK+) and two C-terminal truncated TrkB receptors (TrkB-TK-and TrkB-Shc) (Fig. 1) . Receptor dimer combinations that involve any of the truncated TrkB receptors are capable of binding to BDNF but they cannot activate downstream signaling pathways.
Thus, alterations in the expression ratio of full-length (TrkB-TK+) to truncated (TrkB-TK-and TrkB-Shc) TrkB receptors expressed (Eide et al. 1996; Arevalo and Wu 2006) , such as increased TrkB-TK-and/or TrkB-Shc, will have a profound negative impact on BDNF/TrkB-TK+ signaling. Indeed, both TrkB-TK-and TrkB-Shc, have been demonstrated to inhibit BDNF-stimulated TrkB-TK+ signaling (Eide et al. 1996; Ninkina et al. 1996; Stoilov et al. 2002; ).
The three TrkB isoforms are alternative transcripts generated by alternative exon splicing of the TrkB pre-mRNA (Stoilov et al. 2002) . Splicing of pre-mRNAs is mediated by the spliceosome complex in conjunction with splicing regulatory proteins (Neubauer et al. 1998 ) that target enhancer and silencer sequences in the introns and exons (exonic splicing enhancers (ESE) and exonic splicing silencers (ESS) (Schonrock et al. 2010) ) of genes to regulate exon splicing (Cartegni et al. 2003; Zheng 2004) . In mammals, the splicing regulatory proteins belong to two superfamilies, the serine/arginine (SR) proteins and the heterogeneous nuclear ribonucleoproteins (hnrnp) (Graveley 2000; Dreyfuss et al. 2002) . Inclusion of specific exons within a transcript is determined by the relative levels of SR proteins and hnrnp expressed (Kamma et al. 1995; Hanamura et al. 1998 ).
Considering the importance of BDNF-stimulated TrkB-TK+ signaling for neuronal survival and function, it is unclear why the truncated TrkB receptors are generated. The regulation of TrkB alternative transcript expression begins at the level of pre-mRNA splicing (alternative exon splicing) where each specific transcript variant is first generated. The difference between each TrkB transcript variant lies in the C-terminal domain. Through alternative splicing, the C-terminal domain of TrkB-TK+ is encoded by exons 15, 17-18, 20-24, which allows the expression of a full-length tyrosine kinasecontaining receptor. The C-terminus of TrkB-TK-and TrkB-Shc is encoded by exons 15-16 and exons 15, 17-19, respectively. Both exons 16 and 19 contain a stop codon and thus lead to the translation of unique C-terminal domains lacking the tyrosine kinase domain (Klein et al. 1990 ). However, TrkB-Shc retains a sarc homology-binding domain (Shc) which is encoded by exon 18 (Stoilov et al. 2002) .
Recently, we characterized the expression levels of TrkB-TK+, TrkB-TK-, and TrkB-Shc in various regions of control and AD brains and found a selective elevation in TrkB-Shc transcript levels in the AD hippocampus . Further, using a neuronal cell-line model, we also showed that overexpression of TrkB-Shc can function as a dominant negative receptor by inhibiting TrkB-TK+ phosphorylation (similar to previous reports (Stoilov et al. 2002) ) but interestingly, can selectively inhibit downstream second messenger signaling activity via ERK1/2 . TrkBShc is a brain-and neuron-specific transcript unlike TrkB-TK+ and TrkB-TK-which have demonstrated expression in glia (Ohira and Hayashi 2003; Ohira et al. 2005b; Ohira et al. 2005a) . Considering that there is progressive neuron and brain volume loss in AD, it is important to establish what role TrkB-Shc plays in AD development and progression.
The selective elevation in TrkB-Shc transcript levels in the AD hippocampus combined with reported alterations in exon splicing in neurodegenerative disease (Gao et al. 2007) imply that mechanisms involved in the regulation of alternative exon splicing are dysregulated in AD. At present, the mechanisms involved in the regulation of TrkB premRNA splicing and alternative transcript production have not been described. In this current study, we delineate how increases in TrkB-Shc alternative transcripts occur in AD by defining the factors involved in regulating TrkB pre-mRNA splicing.
Methods

Human brain tissue
The human hippocampal and cerebella brain tissues utilized in this study comprised n=6 controls and n=6 AD cases and were supplied following approvals from the Sydney Brain Bank and New South Wales Tissue Resource Centre, Sydney, Australia. A second brain cohort was used to assess changes in gene expression in the temporal cortex. This brain cohort comprised n=8 controls and n=9 AD cases (generously provided by Professor Glenda Halliday). All brain donors were participants in ethically approved longitudinal research programs, and the data collected and brain collection procedures approved for research purposes by Institutional Human Ethics Committees. AD cases fulfilled clinical and pathological NIA-Reagan criteria, as described previously (NIA 1997; Gregory et al. 2006; Kim et al. 2010) , and had Braak neuritic stages V and VI. Demographic data for the cohorts are detailed in Table 1 and Table S1 . Control and AD cases were matched for age and gender where possible. The diagnostic groups did not differ according to age, brain pH, or postmortem interval (PMI) (all p ≥0.12). Samples were taken from the same anatomical regions of the brain, as previously described (Kagedal et al. 2010; Kim et al. 2010; .
Cell culture and treatments
The neuronal cell-line, SHSY5Y were obtained from the American Type Culture
Collection and grown at 37°C in a 5% CO 2 atmosphere. For continuous culture, cells were cultured in RPMI media containing 10% (v/v) FBS supplemented with 2 mM glutamax. For experiments, SHSY5Y cells were differentiated for 9 days using all-trans retinoic acid (ATRA:10 µM) which was added to the culture medium. During differentiation, the differentiation media (growth media + ATRA) was refreshed every 3 days. For transfections, differentiated SHSY5Y cells were transfected using OptiMEM medium and Lipofectamine 2000 (Life Technologies). For treatments, serum-free RPMI media supplemented with N2 was used. For Aβ 42 experiments, cells were treated for 6 h and harvested. No cell-toxicity was observed in any of the treatment conditions at the concentration employed.
Plasmid construction
The TrkB minigene plasmid was cloned by GeneArt (Life Technologies) using insert sequences provided by us: exons 18 to 20 flanked by 1kb of TrkB intronic or intervening sequences ( Fig. 2A and B) . pcDNA3.1-Srp20.1 was cloned using methods previously described (Wong et al. 2008) . Briefly, DNA fragments encoding Srp20 were amplified from SHSY5Y cDNA using the following primer sets: Srp20.1-BamHIF:
CCCAAAGGATCCATGCATCGT; Srp20.1-EcoRIR:
GGGTTTGAATTCCTATTTCCTT. cDNAs were then digested with BamHI and EcoRI restriction endonuclease and ligated into the pcDNA3.1 vector using T4 DNA ligase (Fermentas). Positive clones were verified by sequencing.
In vivo exon splicing assay
Differentiated SHSY5Y cells were either: transiently transfected with the TrkB minigene for 24 h and treated with Aβ 42 , co-transfected with the TrkB minigene and pcDNA3.1-Srp20.1 for 24 h, or transfected with siSrp20 for 72 h ( Fig. 2A and B ). Cells were harvested for total RNA and reverse transcribed into cDNA using established/published protocols (see below) . TrkB splice transcripts generated from the minigene were detected by semi-quantitative PCR using exon 18 forward primers and minigene specific BGH reverse primers (pan primers), exon 18/20 forward primers and BGH reverse primers (TrkB-TK+ transcript specific primers), and exon 18/19 forward and exon 19 intronic reverse primers (TrkB-Shc transcript specific primers) ( Table 2 ).
PCR cycling conditions were: 94°C for 2 min, 40 cycles of 94°C for 30 seconds, 58°C for 10 seconds, and 72°C for 80 seconds (or 30 seconds for PCR products <500 bp); and one cycle of 72°C for 3 min. PCR products were visualized by agarose gel electrophoresis.
Identities of the PCR products have been verified by sequencing. Bands were quantitated by densitometry using Image J (version 1.37v) (National Institutes of Health USA).
Changes in alternative splicing was determined by calculating the ratio of TrkBShc:TrkB-TK+. TrkB-TK+ was used as an internal normalization control for TrkB-Shc expression levels. This was possible as both PCR products were generated using the same PCR primers.
RNA extraction, cDNA synthesis, and quantitative real-time PCR (qPCR)
Total RNA was extracted from tissues (20 mg) and cells using β-Actin did not vary with treatment or between control and AD cases in any brain region examined (all p>0.06). Details on housekeeping gene selection have been published ).
Aβ 42 preparation
Full details on the preparation (see Supplemental Methods) and characterization of the Aβ 42 monomers, oligomers, and fibril preparations are published . For experiments, 1 µM was used as the final concentration.
Western blotting
Cells were harvested for total protein using RIPA buffer supplemented with protease (Sigma) and phosphatase (Pierce) inhibitor cocktails. Protein concentrations were determined by the bicinchoninic acid method. Twenty micrograms of cell lysates were mixed with 5 × SDS loading buffer (containing β-mercaptoethanol), boiled at 95ºC for 5 min, and separated on 10% SDS-PAGE gels. Proteins were transferred onto nitrocellulose membranes and blocked using 5% (w/v) non-fat milk, 0.1% (v/v) Tween-20 in TBS (TBST) at room temperature for 1 h. Membranes were incubated with primary antibodies: Srp20 (1:5000) (Millipore, cat# MABE116) and β-actin (1:10000) (Sigma, cat# A5060).
Membranes were washed 3 x 10 min with TBST and incubated with mouse peroxidaseconjugated affinity purified secondary antibody for 1 h (Dako). After further washing, bound antibodies were incubated with enhanced chemiluminescence reagent (Millipore) and visualized by autoradiography. Bands were quantitated by densitometry using Image J (version 1.37v) (National Institutes of Health USA). The brightness/contrast of images was adjusted using Adobe Photoshop CS (version 8).
Statistical analysis
Outliers were determined and removed from subsequent analyses using the Grubb's test or if data points were greater or less than two standard deviations from the mean. One control and one AD case were removed from Srp20 qPCR analyses of the hippocampus.
No other outliers were detected in controls or AD cases for Srp20 in the cerebellum and hnrnpK in the hippocampus and cerebellum. One control and one AD case were removed from Srp20 qPCR analyses of the temporal cortex. Statistical analyses were conducted using STATISTICA 7 (StatSoft Inc., 2000, STATISTICA for Windows). Tests for normality were conducted. As all data in this study was normally distributed. Two-tailed unpaired t-tests were used to assess significance in gene expression changes. Pearson's Product Moment correlations were used to determine if any relationship existed between Srp20 and hnrnpK mRNA expression and demographic variables. A p-value less than 0.05 (two-tailed) was considered statistically significant.
Results
Αβ 42 increases TrkB-Shc alternative transcript levels by increasing exon 19 inclusion during alternative splicing
Previously, we observed a significant increase in endogenous TrkB-Shc alternative transcript levels in the hippocampus of AD brains . Moreover, we demonstrated that TrkB-Shc alternative transcript levels in the neuronal cell-line SHSY5Y could be increased by treatment with preparations of Αβ 42 fibrils ). To determine if alternative exon splicing of the TrkB pre-mRNA is altered in AD, particularly by Αβ 42 treatment increasing TrkB-Shc alternative transcript production, we conducted in vivo exon splicing assays utilizing a TrkB minigene construct ( Fig Figure 3A shows a representative image of the PCR products generated from the TrkB minigene using a pan primer set following alternative splicing. PCR products containing exons 18/19/20 correspond to TrkB-Shc (1250 bp) and exons 18/20 correspond to TrkB-TK+ (221 bp). From this, we measured the alternative splicing effect by quantifying the ratio of TrkB-Shc:TrkB-TK+ ( Fig. 3A and B) . In this manner, expression of TrkB-Shc transcripts could be internally normalized by expression of TrkB-TK+ transcripts. We observed a significant increase in the ratio of TrkBShc:TrkB-TK+ mRNA expression when cells were exposed to Αβ 42 fibrils (t=2.44, df=12, p=0.03) (Fig. 3B) . No significant differences in TrkB-Shc:TrkB-TK+ expression ratios were detected when cells were exposed to Αβ 42 monomers and oligomers (all p>0.11).
To validate the in vivo splicing assay, we used two different primer sets to target transcripts corresponding to TrkB-Shc (236 bp) and transcripts corresponding to TrkB-TK+ (197 bp) separately. Compared to the pan primer set, the PCR product sizes for the two transcripts are similar in length. We found that the ratio of TrkB-Shc:TrkB-TK+ calculated from these similar PCR fragment lengths confirm our results found using the pan primers. We found that Αβ 42 fibrils significantly increased the ratio of TrkBShc:TrkB-TK+ (t=5.33, df=12, p=0.0002) (Fig. S1 ). No significant differences in TrkBShc:TrkB-TK+ expression ratios were detected when cells were exposed to Αβ 42 monomers and oligomers (all p>0.20).
In silico screening of splice regulatory proteins predicted to bind to the TrkB pre- 
Srp20 expression is increased in the hippocampus of AD brains and in neuronal celllines treated with Αβ 42 fibrils
We next determined whether mRNA levels of Srp20 and hnrnpK are also correspondingly altered in our control/AD brain cohort. Using hippocampal and cerebella tissue from n=6 controls and n=6 AD cases, we found a significant increase in Srp20 mRNA levels in the AD hippocampus compared to controls (t=3.44, df=8, p=0.009) (Fig.   5A ), but no significant change in the cerebellum (t=1.83, df=10, p=0.1) (Fig. 5B) . monomers, oligomers, and fibrils, we found that Srp20 mRNA levels were significantly increased when cells were exposed to Αβ 42 fibrils (t=3.84, df=15, p=0.002) (Fig. 6) .
Exposure of cells to Αβ 42 monomers or oligomers had no significant effect on Srp20 mRNA levels (all p>0.07). No significant changes were observed in hnrnpK mRNA levels when cells were exposed to all three species of Αβ 42 (all p>0.1) (Figure not shown).
As our results suggested that Srp20 expression is elevated in AD and is affected by AD pathology e.g. Aβ 42 , we next determined if changes in Srp20 expression may be specifically occurring in the AD hippocampus by assessing Srp20 mRNA levels in another brain region also affected in AD, the temporal cortex. We found a significant increase in Srp20 mRNA levels in AD cases compared to controls (t=2.38, df=14, p=0.03) (Fig. S3 ). Srp20 mRNA levels did not correlate with any of the cohort demographics (age: r=-0.35, p>0.81; PMI: r=0.08, p=0.77).
Srp20 can regulate TrkB pre-mRNA splicing to generate TrkB-Shc alternative transcripts
Spr20 overexpression
Following our identification of Srp20 as a possible splice regulatory protein that can modulate TrkB pre-mRNA splicing to favor production of TrkB-Shc transcripts, we then confirmed this by overexpression of Srp20 in differentiated SHSY5Y cells transfected with the TrkB minigene. Figure 7A shows a representative image of the PCR products generated from the TrkB minigene following alternative splicing. Qualitatively, PCR products containing exons 18/19/20 (corresponding to TrkB-Shc) were increased compared to the non-transfected condition whereas PCR products containing exons 18/20
(corresponding to TrkB-TK+) were unchanged with Srp20 overexpression. When we quantitated the ratio of TrkB-Shc:TrkB-TK+ transcript expression, we found a significant increase when Srp20 was overexpressed (t=11.4, df=4, p=0.0003) (Fig. 7B ).
To determine if overexpression of Srp20 can increase the ratio of endogenous control vs. 1000 ng p=0.00006) (Fig. 7C ). When we assessed cellular Srp20 protein levels following Srp20 overexpression and at 1000 ng, we found a significant increase in protein levels (145% increase; t=4.15, df=6, p=0.006) (Fig. 7D) (Fig. 7E ).
Srp20 knockdown
Having observed an increase in TrkB-Shc alternative transcript generation when Srp20 is overexpressed, we then conducted the reciprocal experiments by knocking down Srp20 protein levels. Differentiated SHSY5Y cells were transiently transfected with siRNA targeted to Srp20 and knockdown was conducted for 72 h. We obtained significant knockdown in Srp20 protein levels after 72 h with no significant effect on β-actin protein levels (34% reduction; t=-3.31, df=12, p=0.006) (Fig. 8A ). When we assessed the effect of Srp20 knockdown on TrkB pre-mRNA splicing using the TrkB minigene, qualitatively, we found that PCR products containing exons 18/19/20 (corresponding to TrkB-Shc) were decreased compared to the non-transfected condition whereas PCR products containing exons 18/20 (corresponding to TrkB-TK+) were unchanged with Srp20 kncokdown (Fig. 8B ). When we quantitated the ratio of TrkB-Shc:TrkB-TK+ transcripts expressed from the minigene, we found a significant decrease when Srp20 was knocked-down (t=-2.50, df=14, p=0.03) (Fig. 8C) . Similarly, when we measured the ratio of TrkB-Shc:TrkB-TK+ endogenous mRNA expression, we found a significant decrease in expression levels with Srp20 knockdown compared to the control condition (t=-4.37, df=4, p=0.01) (Fig. 8D ).
Discussion
Previously, we found a selective up-regulation in the neuron-specific TrkB alternative splice transcript, TrkB-Shc, in the hippocampus of AD brains and in a neuronal cell-line (SHSY5Y) treated with Aβ 42 fibrils . As no significant changes were detected for the TrkB-TK+ and TrkB-TK-transcripts in the AD hippocampus, our findings suggested that processes governing alternative exon splicing of the TrkB premRNA may be dysregulated in AD . Alterations in the splicing elements and/or splice regulatory proteins can lead to aberrant splicing (Faustino and Cooper 2003; Tazi et al. 2009 ). To test this hypothesis, we conducted an in vivo exon splicing assay using a TrkB minigene. In comparison to measuring endogenous transcript changes, the exon splicing assay and TrkB minigene has the advantage of allowing selective assessment of pre-mRNA processing and minimizing confounding effects such as miRNA-mediated regulation of mRNA. We found significant increases in exon 19 inclusion in transcripts corresponding to TrkB-Shc as well as the ratio of TrkB-Shc:TrkB-TK+ mRNA expression when cells were exposed to Aβ 42 fibrils, confirming our previous findings where endogenous TrkB-Shc mRNA levels were increased when exposed to Aβ 42 fibrils ).
At present, the mechanisms regulating TrkB alternative transcript production are not known. To establish if TrkB pre-mRNA splicing is dysregulated to favor increased TrkB-Shc alternative transcript levels in AD, we took two approaches. First, we
conducted an in silico screen of the splice regulatory regions of the TrkB gene in the intron/exon junctions around exons 18 and 19 to identify candidate splice regulatory proteins capable of binding to and regulating TrkB pre-mRNA splicing. Next, we examined gene expression levels of candidate splice regulatory proteins identified using two cohorts of control versus AD hippocampi (one from Blalock et al (2004) (NCBI GeoData Sets) (microarray) and the other being our own cohort (qPCR) (Kagedal et al. 2010; Kim et al. 2010; as well as in SHSY5Y cells treated with Aβ 42 .
From the microarray data, we identified Srp20 to be a candidate regulator of TrkB premRNA splicing capable of modulating TrkB-Shc alternative transcript production and then confirmed that Srp20 expression was altered in the AD hippocampus and with Aβ 42 treatment in SHSY5Y cells. The increase in Srp20 expression levels in the hippocampus (and not cerebellum) of our control/AD cohort and with Aβ 42 treatment are consistent with our previous findings for TrkB-Shc mRNA levels ). However, it should be noted that the directional change in Srp20 mRNA levels in our hippocampal brain cohort (increase) was opposite to that observed in the microarray dataset from Blalock et al (2004) (decrease) . This discrepancy between our findings is likely due to cohort differences. In our cohort, all control cases were classed in Braak stage O (no detectable AD pathology) (Table 1) , whereas in Blalock et al. (2004) , the control cases utilized were classed in Braak stage II, suggesting that control cases displayed some AD pathology and plaque accumulation. From this, it may be likely that in Blalock et al.'s (2004) study, the control cases with some AD pathology already displayed increased Srp20 mRNA levels, thus raising baseline expression levels of Srp20. Conversely, the control cases utilized in our current study are likely to have lower baseline Srp20 mRNA levels. An elevation in baseline Srp20 expression likely explains the non-significant increase in Srp20 mRNA levels in the incipient cases and decrease in Srp20 expression in the severe AD cases in Blalock et al.'s (2004) study. By the same reasoning, a lower baseline in Srp20 expression in our cohort also explains why elevated levels of Srp20 expression was observed in the AD cases as well as the small magnitude of increase. It is likely that Srp20 expression levels are increased early in AD pathology and as AD pathology progresses, cell loss may explain the reduction in Srp20 expression over the disease course and in the severe AD stage in Blalock et al.'s study. In support of this, we also found a significant elevation in Srp20 mRNA levels in the temporal cortex. In AD, the temporal cortex is affected following the hippocampus. Thus, elevations in Srp20 expression in the temporal cortex is consistent with an earlier or less severe stage of AD pathology in that brain region.
Another important point to note is that while we found a significant increase in Srp20 expression in the temporal cortex, in our previous study ), we found no significant change in TrkB-Shc mRNA levels in this brain region. This discordance between Srp20 and TrkB-Shc mRNA expression levels in the AD temporal cortex suggests that additional regulatory processes are involved in regulating TrkB premRNA splicing and TrkB-Shc alternative transcript expression which may be brain region specific.
Srp20
Previously, exon selection by Srp20 during alternative splicing was found to be influenced by the presence of suboptimal or weak exon splice acceptor and donor sites (Jumaa and Nielsen 1997) . The splice acceptor site of Srp20 exon 4 contains a weak polypyrimidine tract and the last two nucleotides of exon 4 at the splice donor site do not match the AG consensus. Mutagenesis of the nucleotides in the exon 4 splice acceptor site to generate a strong polypyrimidine tract was found to enable constitutive inclusion of exon 4 by eliminating the need for Srp20 in the pre-mRNA splicing process (Jumaa and Nielsen 1997) . Moreover, the Drosophila homologue of Srp20, RBP1, has also been shown to activate a polypyrimidine tract in the 3' splice acceptor site in dsx (Heinrichs and Baker 1995) . In the TrkB pre-mRNA, we found a putative splice acceptor site in exon 19 (Fig. S4) , suggesting that splicing of exon 19 can be regulated by Srp20. Indeed, we found that cellular overexpression of Srp20 increased exon 19 inclusion in alternative splicing to increase the ratio of exon 18/19/20:exon 18/20 PCR products (corresponding to the ratio of TrkB-Shc:TrkB-TK+ transcripts) in our in vivo splicing assay using the TrkB minigene. Moreover, when we measured endogenous alternative splicing in SHSY5Y cells overexpressing Srp20 or with Srp20 protein knocked down, we found corresponding changes in the ratio of TrkB-Shc:TrkB-TK+ expression. Modulation of Srp20 expression had little to no effect on alternative splicing of exon 18 to 20 to generate TrkB-TK+ transcripts in the in vivo exon splicing assay. This would suggest that Srp20 may be a specific splice regulatory factor for TrkB-Shc transcript production.
Pre-mRNA splicing dysregulation and disease
Dysregulation in mRNA splicing has been implicated in a range of human diseases (Faustino and Cooper 2003; Tazi et al. 2009 ). The most compelling evidence to link dysregulation of exon splicing to neurodegeneration comes from findings in patients with frontotemporal dementia with Parkinsonism. Altered splicing of adult-specific tau exon SR proteins including 9G8 and Srp75 as well as hnrnpG and hnrnpE2 (Gao et al. 2007; Wang et al. 2011) . Point mutations in the splice regulatory region that affect splice factor binding or alterations in splice factor regulation (e.g. by phosphorylation) can all modulate tau exon 10 splicing (Gao et al. 2007; Ding et al. 2011; Wang et al. 2011) . Our current finding that Srp20 can modulate the inclusion/exclusion of exon 19 during TrkB pre-mRNA splicing to modulate TrkB-Shc transcript production and that its expression is elevated in AD suggests that dysregulated exon splicing may contribute to the neurotrophin signaling dysfunction observed in AD. However, it should be noted that dysregulation in exon splicing is one of multiple molecular changes that occur in AD that is capable of disrupting BDNF/TrkB-TK+ signaling and contribute to neurodegeneration.
In summary, we demonstrate that TrkB pre-mRNA splicing can be regulated by the SR protein Srp20, and that elevated expression levels of Srp20 in AD may contribute to the selective increase in TrkB-Shc transcript levels we previously reported in AD (Fig. 9) . Elevated levels of Srp20 increase exon 19 inclusion during splicing of the TrkB pre-mRNA to increase TrkB-Shc transcript expression. This increase in TrkBShc expression may then interfere with BDNF/TrkB-TK+ signaling by acting as a neurotrophin sink or by acting as a dominant negative receptor by forming inactive heterodimers unable to initiate second messenger signaling to activate cell survival pathways (Biffo et al. 1995; Eide et al. 1996; Ninkina et al. 1996; Fryer et al. 1997 ) ( 
